FIELD: biotechnologies.
SUBSTANCE: invention relates to biotechnology and production of vaccines against canine distemper, specifically to a method for indirect determination of the concentration of canine distemper virions in raw material for vaccines using a double mathematical differential for the sigmoid crossing point during amplification of the CDVgp1 gene site. Main advantage of the offered invention is the possibility to determine indirectly the concentration of CDV virions in non-inactivated raw material for culture vaccines. Offered invention suggests combination of molecular-biological research of non-inactivated virus suspension of canine distemper agent with methods of mathematical data analysis that increases accuracy, specificity and sensitivity of method. In the present invention, the relationship between the CDV virion concentration and values of Cp-NSI points is presented in the form of a mathematical function: CCDV=-0.3012 × Cp-CDVgp1 + 10.37 with high reliability of approximation (R2=0.9953) and efficiency of amplification 100.08%.
EFFECT: presented model enables the indirect determination of the canine distemper virion concentration in the vaccine raw material.
2 cl, 4 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INDIRECT DETERMINING OF TITRE OF INFECTIOUS ACTIVITY OF CAUSATIVE AGENT OF CANINE DISTEMPER IN RAW MATERIALS FOR VACCINES USING METHOD OF REVERSE TRANSCRIPTION AND AMPLIFICATION REACTION IN REAL TIME | 2023 |
|
RU2815533C1 |
| METHOD FOR DETERMINING TITRE OF INFECTIOUS ACTIVITY OF CANINE DISTEMPER AGENT IN RAW MATERIAL FOR MAKING CULTURE INACTIVATED VACCINES | 2024 |
|
RU2831062C1 |
| METHOD FOR MEDIATED DETERMINATION OF RIBONUCLEOPROTEIN CONCENTRATION OF CANINE DISTEMPER AGENT IN RAW MATERIAL FOR VACCINES BY DATA OF QUANTITATIVE ASSESSMENT CYCLE DURING N-GENE AMPLIFICATION | 2023 |
|
RU2829837C1 |
| METHOD FOR DETERMINING CONCENTRATION OF VIRIONS OF CAUSATIVE AGENT OF CANINE PARVOVIRAL ENTERITIS IN RAW MATERIAL FOR VACCINES | 2023 |
|
RU2827231C1 |
| METHOD FOR DETERMINING CONCENTRATION OF FELINE CALICIVIRUS VIRIONS IN RAW MATERIAL FOR WHOLE VIRION VACCINES | 2024 |
|
RU2838181C1 |
| METHOD FOR DIFFERENTIATING ROCKBORN STRAIN OF CANINE DISTEMPER VIRUS FROM OTHER CDV STRAINS | 2024 |
|
RU2840521C1 |
| METHOD FOR INDIRECTLY DETERMINING THE TITER OF THE INFECTIOUS ACTIVITY OF FMDV IN NON-INACTIVATED RAW MATERIALS FOR VACCINES USING A MATHEMATICAL DOUBLE DIFFERENTIAL OF THE CROSSING POINT DATA DURING AMPLIFICATION OF VIRAL CDNA | 2022 |
|
RU2793900C1 |
| METHOD FOR INDIRECT DETERMINATION OF INFECTIOUS ACTIVITY TITRE OF CAUSATIVE AGENT OF INFECTIOUS FELINE RHINOTRACHEITIS IN RAW MATERIAL FOR VACCINE USING SECOND-ORDER DIFFERENTIAL OF POINT OF INTERSECTION OF LOGISTIC CURVE OF AMPLIFICATION REACTION OF UL35 GENE REGION | 2023 |
|
RU2823781C1 |
| KIT OF SPECIFIC OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND A FLUORESCENTLY LABELED PROBE FOR THE CANINE MORBILLIVIRUS (CANINE DISTEMPER VIRUS, CDV) NUCLEOCAPSID PROTEIN (N) GENE FRAGMENT FOR THE DETECTION OF CANINE DISTEMPER (CARRÉ DISEASE, DISTEMPER) IN DOGS - REAL-TIME PCR TEST SYSTEM | 2022 |
|
RU2803069C1 |
| METHOD FOR INDIRECT DETERMINATION OF CONCENTRATION OF A-ANTIGEN OF INDUSTRIAL STRAIN "VGNKI" OF CAUSATIVE AGENT OF INFECTIOUS HEPATITIS OF DOGS IN RAW MATERIAL FOR CULTURAL VACCINES ACCORDING TO QUANTITATIVE ASSESSMENT CYCLE DURING AMPLIFICATION OF TARGET REGION OF ORF25-GENE | 2023 |
|
RU2823930C1 |
